Australia's Race Oncology jumps on progress in Phase 1 cancer drug trial

Racura Oncology

19/06/2025 03:46

** Shares of Race Oncology RAC.AX rise 7.1% to A$1.36, their highest since May 30

** Biopharmaceutical co completes first safe dosing with a combination of its RC220 and doxorubicin drugs for the treatment of advanced solid tumour in Phase 1 clinical trial

** Stock on track for best day since May 1, if gains hold

** About 148,945 shares change hands, 1.2x the 30-day average of 120,519

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)

 ((JasmeenAraIslam.Shaikh@thomsonreuters.com;))